drugset / Trial / NCT00870025

Human Chorionic Gonadotropin (hCG) Priming Prior to Controlled Ovarian Hyperstimulation (COH) in Poor Responder In Vitro Fertilization (IVF) Patients

NCT00870025

Phase 4 Completed 60 enrolled IVI Madrid
RandomizedParallel-groupQuadruple-blindTreatment

Summary

There is a decline in androgen concentration with ovarian aging. Also, ovarian response to COH in IVF cycles diminishes with ovarian aging. Recent evidence suggest that testosterone or DHEA may improve ovarian response in poor prognosis patients by increasing intraovarian androgen concentration. A physiological way to induce androgen synthesis within the ovary is to stimulate theca cells androgen production by hCG stimulation. By doing this in the previous cycle we might expect a better response to COH.

Timeline

Start
2008-10
Primary completion
2010-09
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator human chorionic gonadotropin Protein / enzyme biologic 200 iu Subcutaneous

Indications